BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BioCentury | Oct 19, 2017
Company News

Management tracks: Neurocrine, Cellect, Marina

Neurology and endocrine company Neurocrine Biosciences Inc. (NASDAQ:NBIX) said President, COO and Interim CFO David-Alexander Gros is stepping down. CEO Kevin Gorman will serve as interim CFO while the company seeks a replacement. Stem cell...
BioCentury | Apr 20, 2017
Clinical News

ApoGraft: Ph I/II ApoGraft01 ongoing

An independent DSMB approved the enrollment of the next 2 patients in the first cohort of the open-label, Israeli Phase I/II ApoGraft01 trial evaluating transplanted ApoGraft exposed to FASL. The DSMB made the recommendation after...
BioCentury | Feb 9, 2017
Clinical News

ApoGraft: Ph I/II started

Cellect began an open-label, Israeli Phase I/II trial to evaluate transplanted ApoGraft exposed to 10, 25, 50 or 100 ng/mL FASL in about 12 patients undergoing allogeneic stem cell transplantation (ASCT) from a matched related...
BioCentury | Dec 2, 2016
Company News

Cellect, Hadassah deal

Hadassah's Hadasit Ltd. technology transfer arm partnered with Cellect to conduct preclinical studies of Cellect’s ApoGraft to treat graft-versus-host disease (GvHD). Hadassah will conduct the studies. ApoGraft consists of mobilized peripheral blood cells (MPBC) for...
BioCentury | Oct 3, 2016
Finance

Reasonable rally

Steve Edelson, Senior Editor It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in the...
BioCentury | Aug 1, 2016
Financial News

Cellect completes follow-on

Cellect Biotechnology Ltd. (Tel Aviv:CLBD; NASDAQ:APOP), Kfar Saba, Israel Business: Gene/Cell therapy Date completed: 2016-07-29 Type: Follow-on Raised: $8.4 million Shares: 1.3 million Price: $6.50 Shares after offering: 5.4 million Underwriters: H.C. Wainwright; Joseph Gunnar...
BioCentury | Jul 11, 2016
Financial News

Cellect Biomed proposes follow-on

Cellect Biomed Ltd. (Tel Aviv:CLBD), Tel Aviv, Israel Business: Gene/Cell therapy Date announced: 2016-07-07 Type: Follow-on To be raised: Up to $10 million Shares: TBD Price prior: NIS1.59 Underwriters: H.C. Wainwright; Chardan Capital Markets Note:...
BioCentury | Apr 25, 2016
Company News

Cellect Biomed, Accellta deal

Cellect granted Accellta non-exclusive rights to evaluate apoptotic induction-based technology. Accellta will evaluate if the technology can grow its pluripotent stem cells “safely and in a shorter time.” Cellect will receive an upfront payment of...
BioCentury | Feb 22, 2016
Financial News

Cellect Biomed completes private placement

Cellect Biomed Ltd. (Tel Aviv:CLBD), Tel Aviv, Israel Business: Gene/Cell therapy Date completed: 2016-02-16 Type: Private placement Raised: NIS8 million ($2.1 million) Price: NIS1.39 Shares outstanding prior: 75.9 million Investor: Private investors WIR Staff...
Items per page:
1 - 10 of 32
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BioCentury | Oct 19, 2017
Company News

Management tracks: Neurocrine, Cellect, Marina

Neurology and endocrine company Neurocrine Biosciences Inc. (NASDAQ:NBIX) said President, COO and Interim CFO David-Alexander Gros is stepping down. CEO Kevin Gorman will serve as interim CFO while the company seeks a replacement. Stem cell...
BioCentury | Apr 20, 2017
Clinical News

ApoGraft: Ph I/II ApoGraft01 ongoing

An independent DSMB approved the enrollment of the next 2 patients in the first cohort of the open-label, Israeli Phase I/II ApoGraft01 trial evaluating transplanted ApoGraft exposed to FASL. The DSMB made the recommendation after...
BioCentury | Feb 9, 2017
Clinical News

ApoGraft: Ph I/II started

Cellect began an open-label, Israeli Phase I/II trial to evaluate transplanted ApoGraft exposed to 10, 25, 50 or 100 ng/mL FASL in about 12 patients undergoing allogeneic stem cell transplantation (ASCT) from a matched related...
BioCentury | Dec 2, 2016
Company News

Cellect, Hadassah deal

Hadassah's Hadasit Ltd. technology transfer arm partnered with Cellect to conduct preclinical studies of Cellect’s ApoGraft to treat graft-versus-host disease (GvHD). Hadassah will conduct the studies. ApoGraft consists of mobilized peripheral blood cells (MPBC) for...
BioCentury | Oct 3, 2016
Finance

Reasonable rally

Steve Edelson, Senior Editor It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in the...
BioCentury | Aug 1, 2016
Financial News

Cellect completes follow-on

Cellect Biotechnology Ltd. (Tel Aviv:CLBD; NASDAQ:APOP), Kfar Saba, Israel Business: Gene/Cell therapy Date completed: 2016-07-29 Type: Follow-on Raised: $8.4 million Shares: 1.3 million Price: $6.50 Shares after offering: 5.4 million Underwriters: H.C. Wainwright; Joseph Gunnar...
BioCentury | Jul 11, 2016
Financial News

Cellect Biomed proposes follow-on

Cellect Biomed Ltd. (Tel Aviv:CLBD), Tel Aviv, Israel Business: Gene/Cell therapy Date announced: 2016-07-07 Type: Follow-on To be raised: Up to $10 million Shares: TBD Price prior: NIS1.59 Underwriters: H.C. Wainwright; Chardan Capital Markets Note:...
BioCentury | Apr 25, 2016
Company News

Cellect Biomed, Accellta deal

Cellect granted Accellta non-exclusive rights to evaluate apoptotic induction-based technology. Accellta will evaluate if the technology can grow its pluripotent stem cells “safely and in a shorter time.” Cellect will receive an upfront payment of...
BioCentury | Feb 22, 2016
Financial News

Cellect Biomed completes private placement

Cellect Biomed Ltd. (Tel Aviv:CLBD), Tel Aviv, Israel Business: Gene/Cell therapy Date completed: 2016-02-16 Type: Private placement Raised: NIS8 million ($2.1 million) Price: NIS1.39 Shares outstanding prior: 75.9 million Investor: Private investors WIR Staff...
Items per page:
1 - 10 of 32